Diagnosis and classification of optic neuritis

Axel Petzold 1Clare L Fraser 2Mathias Abegg 3Raed Alroughani 4Daniah Alshowaeir 5Regina Alvarenga 6Cécile Andris 7Nasrin Asgari 8Yael Barnett 9Roberto Battistella 10Raed Behbehani 11Thomas Berger 12Mukharram M Bikbov 13Damien Biotti 14Valerie Biousse 15Antonella Boschi 16Milan Brazdil 17Andrei Brezhnev 18Peter A Calabresi 19Monique Cordonnier 20Fiona Costello 21Franz M Cruz 22Leonardo Provetti Cunha 23Smail Daoudi 24Romain Deschamps 25Jerome de Seze 26Ricarda Diem 27Masoud Etemadifar 28Jose Flores-Rivera 29Pedro Fonseca 30Jette Frederiksen 31Elliot Frohman 32Teresa Frohman 32Caroline Froment Tilikete 33Kazuo Fujihara 34Alberto Gálvez 35Riadh Gouider 36Fernando Gracia 37Nikolaos Grigoriadis 38José M Guajardo 39Mario Habek 40Marko Hawlina 41Elena H Martínez-Lapiscina 42Juzar Hooker 43Jyh Yung Hor 44William Howlett 45Yumin Huang-Link 46Zhannat Idrissova 47Zsolt Illes 48Jasna Jancic 49Panitha Jindahra 50Dimitrios Karussis 51Emilia Kerty 52Ho Jin Kim 53Wolf Lagrèze 54Letizia Leocani 55Netta Levin 56Petra Liskova 57Yaou Liu 58Youssoufa Maiga 59Romain Marignier 60Chris McGuigan 61Dália Meira 62Harold Merle 63Mário L R Monteiro 64Anand Moodley 65Frederico Moura 66Silvia Muñoz 67Sharik Mustafa 68Ichiro Nakashima 69Susana Noval 70Carlos Oehninger 71Olufunmilola Ogun 72Afekhide Omoti 73Lekha Pandit 74Friedemann Paul 75Gema Rebolleda 76Stephen Reddel 77Konrad Rejdak 78Robert Rejdak 79Alfonso J Rodriguez-Morales 80Marie-Bénédicte Rougier 81Maria Jose Sa 82Bernardo Sanchez-Dalmau 83Deanna Saylor 84Ismail Shatriah 85Aksel Siva 86Hadas Stiebel-Kalish 87Gabriella Szatmary 88Linh Ta 89Silvia Tenembaum 90Huy Tran 91Yevgen Trufanov 92Vincent van Pesch 93An-Guor Wang 94Mike P Wattjes 95Ernest Willoughby 96Magd Zakaria 97Jasmin Zvornicanin 98Laura Balcer 99

Affiliations


Abstract

There is no consensus regarding the classification of optic neuritis, and precise diagnostic criteria are not available. This reality means that the diagnosis of disorders that have optic neuritis as the first manifestation can be challenging. Accurate diagnosis of optic neuritis at presentation can facilitate the timely treatment of individuals with multiple sclerosis, neuromyelitis optica spectrum disorder, or myelin oligodendrocyte glycoprotein antibody-associated disease. Epidemiological data show that, cumulatively, optic neuritis is most frequently caused by many conditions other than multiple sclerosis. Worldwide, the cause and management of optic neuritis varies with geographical location, treatment availability, and ethnic background. We have developed diagnostic criteria for optic neuritis and a classification of optic neuritis subgroups. Our diagnostic criteria are based on clinical features that permit a diagnosis of possible optic neuritis; further paraclinical tests, utilising brain, orbital, and retinal imaging, together with antibody and other protein biomarker data, can lead to a diagnosis of definite optic neuritis. Paraclinical tests can also be applied retrospectively on stored samples and historical brain or retinal scans, which will be useful for future validation studies. Our criteria have the potential to reduce the risk of misdiagnosis, provide information on optic neuritis disease course that can guide future treatment trial design, and enable physicians to judge the likelihood of a need for long-term pharmacological management, which might differ according to optic neuritis subgroups.

Conflict of interest statement

Declaration of interests AP received grant support for remyelination trials in multiple sclerosis to the Amsterdam University Medical Centre, Department of Neurology, MS Centre (RESTORE trial), and UCL, London RECOVER trial; received grant fees from Fight for Sight (nimodipine in optic neuritis trial); received royalties or licenses from Up-to-Date (Wolters Kluwer) for a book chapter; received speaker fees for the Heidelberg Academy; participates on advisory board for SC Zeiss OCTA Angi-Network, and the SC Novartis OCTiMS study; holds leadership roles for governing board IMSVISUAL; was chairman of ERN-EYE Neuro-ophthalmology (until Oct, 2020); is board member of National Dutch Neuro-ophthalmology Association; received equipment from OCTA from Zeiss (Plex Elite); and received medical writing support from Novartis for a manuscript (https://doi.org/10.1002/acn3.51473). CF received consulting fees from Invex Therapeutics; received speaker honoraria from University of Dunedin; and holds leadership as Director of Royal Australian and New Zealand College of Ophthalmologists. VB received personal fees as consultant for Gensight and Neurophoenix. PC obtained grants from Annexon, Biogen, Genentech; received royalties from Cambridge Press for an OCT book; received consulting fees from Disarm Therapeutics, Nervgen, Biogen, Avidea; received honoraria from NY Academy of Sciences; and received equipment from Myelin Repair Foundation, Academic CME, Neuraly, and Landos. FC received speaker honoraria from Alexion, Accure Therapeutics, and the Sumiara Foundation. RDe obtained consulting fees from Alexion. JdS received consulting fees from Biogen, Teva, BMS Celegen, Roche, Novartis, Janssen, Merck, Alexion, CSL Behring; and honoraria from Biogen, Teva, BMS Celegen, Roche, Novartis, Janssen, Merck, Alexion, and CSL Behring. JFR received consulting fees from Roche, and Sanofi. EF holds honoraria from Alexion, Genzyme, Biogen, Novartis, and Janssen. TF holds honoraria from Alexion. CFT received honoraria from Novartis; and received support for attending meetings and travel from Novartis and Teva. KF obtained grants from Ministry of Education, Science and Technology of Japan as well as the Ministry of Health, Welfare and Labor of Japan; received consulting fees from Alexion Chugai-Roche Mitsubishi Tanabe, Novartis, Biogen, Eisai, Takeda, Teijin, Viela Bio, UCB, Merck, Japan Tobacco Pharma, and Abbvie; received honoraria from Alexion, Chugai-Roche, Mitsubishi Tanabe, Novartis, Biogen, Eisai, Takeda, Asahi Kasei Medical, Teijin, and Bayer; participated on a data safety monitoring board or advisory board from Alexion, Chugai, Mitsubishi Tanabe, Novartis, Biogen, Eisai, Takeda, Asahi Kasei Medical, Teijin, UCB, and Viela Bio; and received medical writing support from Oxford PharmaGenesis and Apothecom. RG acquired personal fees for participation on data safety monitoring boards, and served on the advisory boards for Biogen, Hikma, Merck, Roche, and Sanofi as well as receiving a grant from Roche. FG received grants or contracts from Roche (NMO epidemiologic studies) and Novartis (MS epidemiologic studies); received honoraria from for lectures from Roche, Novartis, Stendhal, and Merck; received support for attending meetings from the European Charcot Foundation, and ECTRIMS; and reports leadership of FOCEM (Foro Centroamericano y del Caribe de la Esclerosis Múltiple y otras enfermedades desmielinizantes del Sistema Nervioso Central) and Academia Panameña de Medicina y Cirugía (both unpaid). MHab obtained honoraria from Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva-Teva, Roche, and Zentiva; received support for attending meetings from Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva-Teva, and Roche; and participated on advisory board for Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva-Teva, and Roche. ZIl obtained grants or contracts from Biogen and Alexion; received honoraria from Biogen, Novartis, Roche, Merck, and Alexion; received payment for expert testimony from Roche; received support for attending meetings and travel from Biogen and Sanofi; and participated on a data safety monitoring board or advisory board from Biogen, Novartis, Merck, Sanofi, Roche, and Alexion. HJK received grants or contracts from National Research Foundation of Korea, Aprilbio, and Eisai; received consulting fees from Aprilbio, Daewoong, HanAll BioPharma, MDimune, Roche, Sanofi Genzyme, Teva-Handok, UCB, and Viela Bio; and received honoraria from Alexion, Biogen, Celltrion, Eisai, GC Pharma, Merck Serono, Novartis, Sanofi Genzyme, and Teva-Handok. RM received consulting fees from UCB, Alexion, Merck, Viela Bio, Novartis, and Roche; and participated on an advisory board for Viela Bio and Roche. FP obtained research support from Alexion; received grants or contracts from German Ministry for Research Support Recipient Charité Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck, Serono, Novartis, Bayer, Roche, Parexel, and Almirall; received honoraria from the Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Viela Bio, Roche, UCB, Mitsubishi Tanabe, and Celgene; received support for attending meetings from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe, and Celgene; participated on an advisory board for Celgene, Roche, UCB, Merck; and reports leadership as academic editor for Plos One, and associate editor for Neurology, Neuroimmunology, and Neuroinflammation. MBR received support for attending meeting from Novartis. BSD received consulting fees from Chiesi; received honoraria from Chiesi and Sanofi; received support for attending meetings from Bausch + Lomb; participated on an advisory board for Chiesi; and has stock options from Accure Therapeutics. DS received grants or contracts from National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH), American Academy of Neurology (AAN), National Institute of Aging (NIA), National Multiple Sclerosis Society (NMSS), and United States Department of State; and was a committee member for Multiple Sclerosis International Federation (MSIF) and American Neurological Association (ANA). AS received grants or contracts from the Turkish MS society, and Istanbul University Research Support Grants; received consulting fees from Roche, Merck Serono, Biogen, Gen Pharma of Türkiye, Sanofi Genzyme, and Novartis; received honoraria from Sanofi Genzyme, Novartis, Roche, and Teva; and received support for attending meetings from Sanofi Genzyme. VvP obtained grants or contracts from Biogen; received consulting fees from Biogen, Merck, Sanofi, BMS, Novartis, Janssen, Almirall, and Roche; received honoraria from Biogen, Merck, Sanofi, BMS, Novartis, Roche; and received support for attending meetings from Biogen, Roche, and Almirall. MPW received royalties from Springer Healthcare and Elsevier; received consulting fees from Biogen, Roche, Biologix, Novartis, BMS-Celgene, Imcyse, Merck Serono, Sanofi Aventis, IXICO, and Icometrix; received honoraria from Bayer, Biogen, Biologix, Genilac, Novartis, Medison, Merck Serono, Roche, Sanofi Aventis, and BMS-Celgene; and participated on a data safety monitoring board for VU University Medical Center. LB received consulting fees as editor for the Journal of Neuro-Ophthalmology. GTP is an Emeritus editor for Neuro-ophthalmology. All other authors declare no competing interests.


Similar articles

[OPTIC NEURITIS - CLASSIFICATION, MANAGEMENT AND TREATMENT].

Almer Z.Harefuah. 2022 Oct;161(10):645-651.PMID: 36315205 Review. Hebrew.

Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein.

Ducloyer JB, Michel L, Wiertlewski S, Lebranchu P.Eur J Ophthalmol. 2019 Mar;29(2):257-261. doi: 10.1177/1120672118784797. Epub 2018 Jul 4.PMID: 29972029

Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.

Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL.Lancet Neurol. 2023 Jan;22(1):89-100. doi: 10.1016/S1474-4422(22)00187-9. Epub 2022 Sep 22.PMID: 36155661 Review.

Update on Pediatric Optic Neuritis.

Gise RA, Heidary G.Curr Neurol Neurosci Rep. 2020 Mar 3;20(3):4. doi: 10.1007/s11910-020-1024-x.PMID: 32124097 Review.

Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica.

Ambika S, Durgapriyadarshini S, Padmalakshmi K, Noronha V, Arjundas D.Indian J Ophthalmol. 2022 Jan;70(1):194-200. doi: 10.4103/ijo.IJO_887_21.PMID: 34937238 Free PMC article.


Cited by

Collapsin response mediator protein 5-associated optic neuropathy: clinical characteristics, radiologic clues, and outcomes.

Yan R, Mao Y, Zeng H, Liu Q, Jiang H, Peng J, Yang Q, Cui S, Liu L, Guo Y, Wang J.Front Neurol. 2023 Jun 28;14:1163615. doi: 10.3389/fneur.2023.1163615. eCollection 2023.PMID: 37448746 Free PMC article.

Idiopathic Optic Neuritis Should Neither Be Defined as a Subtype nor an Early Sign of Multiple Sclerosis.

Wei S, Du Y, Luo W.Neuroophthalmology. 2023 Apr 27;47(4):230-231. doi: 10.1080/01658107.2023.2205931. eCollection 2023.PMID: 37434669 No abstract available.

Diagnosis of Optic Disc Oedema: Fundus Features, Ocular Imaging Findings, and Artificial Intelligence.

Bouthour W, Biousse V, Newman NJ.Neuroophthalmology. 2023 Feb 16;47(4):177-192. doi: 10.1080/01658107.2023.2176522. eCollection 2023.PMID: 37434667 Review.

Cohort profile: rationale and methods of UK Biobank repeat imaging study eye measures to study dementia.

Foster PJ, Atan D, Khawaja A, Lotery A, MacGillivray T, Owen CG, Patel PJ, Petzold A, Rudnicka A, Sun Z, Sheard S, Allen N; UK Biobank and UK Biobank Eye and Vision Consortium.BMJ Open. 2023 Jun 23;13(6):e069258. doi: 10.1136/bmjopen-2022-069258.PMID: 37355273 Free PMC article.

Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting With Orbital Apex Syndrome.

Sulaiman FN, Kamardin NF, Sultan Abdul Kader MI, Ch'ng H, Wan Abdul Halim WH.Cureus. 2023 May 13;15(5):e38975. doi: 10.7759/cureus.38975. eCollection 2023 May.PMID: 37313108 Free PMC article.


KMEL References